<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541008</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000569863</org_study_id>
    <secondary_id>FRE-FNCLCC-GEP-03-0603</secondary_id>
    <secondary_id>EU-20761</secondary_id>
    <secondary_id>EUDRACT-2006-003339-62</secondary_id>
    <secondary_id>PFIZER-FRE-FNCLCC-GEP-03-0603</secondary_id>
    <nct_id>NCT00541008</nct_id>
  </id_info>
  <brief_title>Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer</brief_title>
  <official_title>Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well sunitinib works as first-line therapy in&#xD;
      treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the objective tumor response rate in patients with locally advanced or&#xD;
           metastatic papillary renal cell carcinoma treated with sunitinib malate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the safety of this drug in these patients.&#xD;
&#xD;
        -  To determine time-to-event variables of overall survival, time to disease progression,&#xD;
           time to response, and duration of response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sunitinib malate once a day on days 1-28. Treatment repeats every 6&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 28 days and then periodically&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2007</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <enrollment type="Actual">92</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of papillary renal cell carcinoma&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
               -  Type I or type II disease&#xD;
&#xD;
          -  Progressive disease&#xD;
&#xD;
          -  Measurable disease defined by RECIST criteria as at least 1 lesion at least 2 cm in&#xD;
             length by conventional CT scan techniques or at least 1 cm by spiral CT scan&#xD;
&#xD;
          -  No brain metastases including treated and nonprogressive metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 3 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  INR ≤ 1.7 or PT ≤ 6 seconds over ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Patients must be affiliated to a Social Security System&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  NCI CTC grade 3 hemorrhage within 4 weeks prior to start of study treatment&#xD;
&#xD;
          -  Diagnosis of any second malignancy within the past 3 years except for basal cell&#xD;
             carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix that has been&#xD;
             adequately treated with no evidence of recurrent disease within the past 12 months&#xD;
&#xD;
          -  Spinal cord compression, carcinomatous meningitis, or leptomeningeal disease&#xD;
&#xD;
          -  Any of the following within the past 12 months prior to study drug administration:&#xD;
&#xD;
               -  Severe/unstable angina&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Coronary artery bypass graft&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident including transient ischemic attack&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
          -  Any of the following conditions:&#xD;
&#xD;
               -  Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2&#xD;
&#xD;
               -  Atrial fibrillation of any grade&#xD;
&#xD;
               -  Prolongation of the QTc interval to &gt; 450 msec for males or &gt; 470 msec for&#xD;
                  females&#xD;
&#xD;
          -  Hypertension that cannot be controlled by medications&#xD;
&#xD;
          -  Inability to swallow oral medications or presence of active inflammatory bowel&#xD;
             disease, partial or complete bowel obstruction, or chronic diarrhea&#xD;
&#xD;
          -  Known HIV or AIDS infection&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical condition potentially hampering&#xD;
             compliance with the study protocol and the follow-up schedule&#xD;
&#xD;
          -  Patients deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all toxic effects of any prior local treatment to CTCAE version 3.0&#xD;
             grade ≤ 1&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
               -  At least 1 week since prior radiotherapy to &lt; 10% of the whole body allowed&#xD;
                  provided side effects are &lt; grade 2 and there is at least one site for evaluation&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent anticoagulant agents or therapeutic&#xD;
             doses of warfarin&#xD;
&#xD;
               -  Low-dose warfarin (up to 2 mg/day) for deep vein thrombosis prophylaxis allowed&#xD;
&#xD;
               -  Low molecular weight heparin allowed&#xD;
&#xD;
          -  No prior specific medical systemic therapy (i.e., first-line therapy)&#xD;
&#xD;
          -  No prior sunitinib malate&#xD;
&#xD;
          -  No prior investigational agents&#xD;
&#xD;
          -  No concurrent treatment on another therapeutic clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Ravaud, MD, PhD</last_name>
    <affiliation>Hopital Saint Andre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital de la Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame de Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Michel</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 papillary renal cell carcinoma</keyword>
  <keyword>type 2 papillary renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

